MICROLEARNING Overactive Bladder in Patients With Benign Prostatic Hyperplasia: Applying the Most Recent Data and Guideline Recommendations to Clinical Practice - Module 1

Statement of Need 

Approximately 14 million men in the United States have symptoms of BPH, and among that group, around 75% exhibit symptoms of OAB. Unfortunately, OAB is underdiagnosed in clinical practice due to a variety of reasons from patient embarrassment or perception that bladder storage symptoms are a normal part of aging to clinician failure to ask about bladder symptoms. Even when OAB is diagnosed, not all patients receive appropriate treatment. Recent revisions to the SUO/AUA guidelines highlight the safety of treating OAB and BPH concomitantly. However, guidelines do not provide information on how to use individual patient characteristics, such as age and comorbidities, to guide treatment selection. 

This educational activity covers best practices for identifying and diagnosing OAB in men with BPH in the primary care and urology settings as well as how to select between current behavioral and pharmacotherapeutic interventions.  

Learning Objectives 

After participating in this education, learners will be able to: 

• Describe factors leading to under-recognition of OAB 

• State key recommendations from AUA guidelines regarding management of OAB in patients with concomitant BPH 

• List therapeutic options for OAB in patients with BPH that are not included in the AUA guidelines 

CREDIT DESIGNATIONS 

Albert Einstein College of Medicine-Montefiore Medical Center designates this live activity for a maximum of 0.25 AMA PRA Category 1 CreditsTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Albert Einstein College of Medicine-Montefiore Medical Center designates this activity for 0.25 nursing contact hours.  Nurses should claim only credit commensurate with the extent of their participation in the activity 

This activity is supported by an educational grant from Sumitomo Pharma America. 

Financial Disclosures 

The "Policy on Identification, Mitigation, and Disclosure of Relevant Financial Relationships" at Albert Einstein College of Medicine-Montefiore Medical Center mandates that all individuals, including faculty, who have control over content in CME/CE activities, must disclose any relevant financial relationships with ineligible companies*, or the absence of such relationships, from the past 24 months to the audience. Any individual in control of content who refuses to disclose, or their disclosed relationships prove to create a conflict of interest will be recused. 

All financial relationships of individual(s) in a position to control the content of this CME/CE activity has been identified and mitigated prior to this educational activity.  

*The ACCME defines an ineligible company as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.  

Diane Newman, DNP, ANP-BC, FAAN, BCB-PMD 
Advisory Board: Sumitomo, Cosm 
Research: Hollister, NIH 

Rachel Shapiro, MS, PA-C does not have any financial relationships or relationships to products or devices with ineligible companies 

Chelsey Goins, PhD does not have any financial relationships or relationships to products or devices with ineligible companies  

Núria Waddington Negrão, PhD does not have any financial relationships or relationships to products or devices with ineligible companies 

Sapana Panday, MPH does not have any financial relationships or relationships to products or devices with ineligible companies 

Una Hopkins, DNP does not have any financial relationships or relationships to products or devices with ineligible companies